Ultra-Sensitive ctDNA Testing Can Locate ctDNA At Baseline In Patients With Primary HR+ Early Breast Cancer, Research Finds

Cancer Network (12/14, Chan) reported “data from the phase 2 PELOPS investigational trial...showed in patients with primary hormone receptor (HR)–positive early breast cancer, ultra-sensitive circulating tumor DNA (ctDNA) testing was able to locate ctDNA at baseline.” According to the results presented at the San Antonio Breast Cancer Symposium, “the presence of ctDNA at baseline in the patient population was linked with a larger pathological tumor size and higher residual cancer burden (RCB) scores after neoadjuvant endocrine therapy.” Furthermore, “persistent ctDNA after neoadjuvant endocrine therapy was associated with higher rates of recurrence...noted” researchers.